Literature DB >> 28969155

Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem.

Garima Yadav1, Bhaskar Thakuria2, Molly Madan3, Vivek Agwan2, Anita Pandey2.   

Abstract

INTRODUCTION: Enterococci are recognized as opportunistic pathogens, as well as commensals in both humans and animals. They are an important cause of nosocomial infections, difficult to treat, as the organism have intrinsic and acquired resistance to many antibiotics. AIM: To isolate and identify clinically relevant Enterococcus up to species level from all the clinical samples processed in the microbiology laboratory and also to study their resistance pattern.
MATERIALS AND METHODS: A prospective study was carried out for a period of one year from May 2014 to April 2015 at the Department of Microbiology, Subharti Medical College, Meerut, Uttar Pradesh, India. A total of 200 isolates of Enterococcus species from 15342 clinical samples obtained from IPD/OPD patients irrespective of age, having suspicion of bacterial infection were processed in the microbiology laboratory. Identification was done with standard biochemical methods. Antibiotic susceptibility testing was done on Muller Hilton agar plate by Kirby Bauer disc diffusion method. High-Level Gentamycin Resistance (HLGR) and High-Level Streptomycin Resistance (HLSR) were further confirmed by Agar dilution method and Broth microdilution method. Vancomycin and linezolid resistance was further confirmed by Agar dilution method and MIC was calculated by using VITEK 2, Biomerieux. All methodology was followed as per Clinical and Laboratory Standards Institute (CLSI) M100-S 24, 2014 guidelines.
RESULTS: E. faecalis (n=169, 84.5%) was the predominant species isolated, followed by E. faecium (n=27, 13.5%) and E. casseliflavus (n=4, 2%). A total of 25 (12.5%) isolates were HLGR, 13 (6.5%) isolates were HLSR and 62 (31%) isolates were HLGR+HLSR. Vancomycin resistance was found in 14 (7%) isolates of which 11 (78.5%) were Van A and 3 (21.4%) were Van B, detected phenotypically as per relative MIC of vancomycin and teicoplanin. Linezolid resistance was seen in 4 (2%) of isolates which were vancomycin as well as high-level gentamycin and high-level streptomycin resistant.
CONCLUSION: Isolation of Enterococcus species resistant to most of the higher antibiotics like vancomycin and linezolid, with high prevalence of High-Level Aminoglycoside Resistance (HLAR), from hospitalized patients is a major concern as such isolates have limited or no therapeutic option.

Entities:  

Keywords:  High-level aminoglycoside resistance; High-level gentamycin-resistance; High-level streptomycin resistance; Linezolid resistant enterococci

Year:  2017        PMID: 28969155      PMCID: PMC5620796          DOI: 10.7860/JCDR/2017/27260.10474

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  17 in total

Review 1.  Enterococcal resistance--an overview.

Authors:  Y A Marothi; H Agnihotri; D Dubey
Journal:  Indian J Med Microbiol       Date:  2005-10       Impact factor: 0.985

2.  Drug resistant enterococci in a south Indian hospital.

Authors:  K G Bhat; C Paul; N C Ananthakrishna
Journal:  Trop Doct       Date:  1998-04       Impact factor: 0.731

3.  Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci.

Authors:  M Baptista; F Depardieu; P Reynolds; P Courvalin; M Arthur
Journal:  Mol Microbiol       Date:  1997-07       Impact factor: 3.501

Review 4.  Management of infections due to resistant enterococci: a review of therapeutic options.

Authors:  D Landman; J M Quale
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

5.  Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis.

Authors:  Lorena Diaz; Pattarachai Kiratisin; Rodrigo E Mendes; Diana Panesso; Kavindra V Singh; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

6.  Case report vancomycin -resistant Enterococcus faecium VanA phenotype: first documented isolation in India.

Authors:  Srujana Mohanty; Benu Dhawan; R S Gadepalli; Rakesh Lodha; Arti Kapil
Journal:  Southeast Asian J Trop Med Public Health       Date:  2006-03       Impact factor: 0.267

7.  Prevalence, outcome and risk factor associated with vancomycin-resistant Enterococcus faecalis and Enterococcus faecium at a Tertiary Care Hospital in Northern India.

Authors:  A Tripathi; S K Shukla; A Singh; K N Prasad
Journal:  Indian J Med Microbiol       Date:  2016 Jan-Mar       Impact factor: 0.985

8.  The first linezolid-resistant Enterococcus faecium in India: High level resistance in a patient with no previous antibiotic exposure.

Authors:  Simit Kumar; Maitreyi Bandyoapdhyay; Mitali Chatterjee; Prabir Mukhopadhyay; Sumon Poddar; Parthajit Banerjee
Journal:  Avicenna J Med       Date:  2014-01

9.  Emergence of vanA gene among vancomycin-resistant enterococci in a tertiary care hospital of North - East India.

Authors:  Chimanjita Phukan; Mangala Lahkar; Swapnil Ranotkar; Kandarpa K Saikia
Journal:  Indian J Med Res       Date:  2016-03       Impact factor: 2.375

10.  Phenotypic & genotypic characterization of vancomycin resistant Enterococcus isolates from clinical specimens.

Authors:  Ira Praharaj; S Sujatha; Subhash Chandra Parija
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

View more
  8 in total

Review 1.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 2.  Microbial Resistance to Antibiotics and Effective Antibiotherapy.

Authors:  Adriana Aurelia Chiș; Luca Liviu Rus; Claudiu Morgovan; Anca Maria Arseniu; Adina Frum; Andreea Loredana Vonica-Țincu; Felicia Gabriela Gligor; Maria Lucia Mureșan; Carmen Maximiliana Dobrea
Journal:  Biomedicines       Date:  2022-05-12

3.  In vitro activity of radezolid against Enterococcus faecium and compared with linezolid.

Authors:  Zhichao Xu; Ying Wei; Yu Wang; Guangjian Xu; Hang Cheng; Junwen Chen; Zhijian Yu; Zhong Chen; Jinxin Zheng
Journal:  J Antibiot (Tokyo)       Date:  2020-07-16       Impact factor: 2.649

4.  Inhibition of the Quorum Sensing System, Elastase Production and Biofilm Formation in Pseudomonas aeruginosa by Psammaplin A and Bisaprasin.

Authors:  Emmanuel T Oluwabusola; Nursheena Parveen Katermeran; Wee Han Poh; Teo Min Ben Goh; Lik Tong Tan; Oluwatofunmilayo Diyaolu; Jioji Tabudravu; Rainer Ebel; Scott A Rice; Marcel Jaspars
Journal:  Molecules       Date:  2022-03-06       Impact factor: 4.411

5.  The occurrence of antibiotic-resistant bacteria on the clothes of nursery teachers in daycare centres.

Authors:  Dominika Žagar; Anamarija Zore; Karmen Godič Torkar
Journal:  J Appl Microbiol       Date:  2022-03-21       Impact factor: 4.059

6.  Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect.

Authors:  Jatapat Hemapanpairoa; Dhitiwat Changpradub; Sudaluck Thunyaharn; Wichai Santimaleeworagun
Journal:  Infect Drug Resist       Date:  2019-07-11       Impact factor: 4.003

7.  Key Takeaways From the U.S. CDC's 2019 Antibiotic Resistance Threats Report for Frontline Providers.

Authors:  Sameer S Kadri
Journal:  Crit Care Med       Date:  2020-07       Impact factor: 7.598

8.  Prevalence of Vancomycin-Resistant Enterococci and Antimicrobial Residues in Wastewater and Surface Water.

Authors:  Kristýna Hricová; Magdaléna Röderová; Petr Fryčák; Volodymyr Pauk; Ondřej Kurka; Kristýna Mezerová; Taťána Štosová; Jan Bardoň; David Milde; Pavla Kučová; Milan Kolář
Journal:  Life (Basel)       Date:  2021-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.